News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Pyxis Oncology reset cash runway reduces near-term financing risk and offers a swing-trade entry at $2.15 with $3.50 target.
  • Lam Research sees strong order momentum from AI-driven wafer-fab demand, prompting a cautious buy on expanding margins and cash flow.
  • Geely's reported battery supply deal with NIO lifts its risk/reward and creates squeeze potential for the thinly traded OTC stock.
  • Design Therapeutics reports dose-dependent four-week gains and will pursue registrational development, prompting a recommend Hold pending longer readouts.
  • H&R Block trades at value levels with steady tax-season cash flow and 4%+ yield, suggested as a 3–6 month income/optionality position.
  • Micron's AI-driven profitability and near-zero debt give it a financing edge and a buy case to ride sustained memory demand.

Latest Articles

Viking Acquisition Corp. II Prices $200 Million IPO, Units to Trade on NYSE

Viking Acquisition Corp. II Prices $200 Million IPO, Units to Trade on NYSE

Viking Acquisition Corp. II completed the pricing of its initial public offering on July 1, 2026, selling 20,000,000 units at $10.00 per unit to raise $200 million. Units are slated to begin trading on the New York Stock Exchange under the symbol VII U, with Class A shares and warrants expected to trade separately under VII and VII WS once split. C…

MediaAlpha Director Nonko Liquidates $427K in MAX Shares Amid Rally

MediaAlpha Director Nonko Liquidates $427K in MAX Shares Amid Rally

MediaAlpha director Eugene Nonko sold 34,491 shares of the company's Class A Common Stock between June 29 and July 1, 2026, generating approximately $427,815 in proceeds. The sales, conducted through both direct transactions and O.N.E. Holdings, LLC, were executed under a Rule 10b5-1 trading plan established to cover tax obligations from Restricted…

CoreWeave Executive McBee Brannin Sells $5.47M in Stock Amid Market Shifts

CoreWeave Executive McBee Brannin Sells $5.47M in Stock Amid Market Shifts

McBee Brannin, CoreWeave's Chief Development Officer, executed a series of Class A Common Stock sales totaling approximately $5.47 million in late June 2026. The transactions, conducted under a Rule 10b5-1 trading plan and to satisfy tax withholding requirements from restricted stock unit vesting, occur as the company's stock price has retreated fr…

Minnesota Closes Wrongful Conviction Review Unit Amid Federal Funding Dispute

Minnesota Closes Wrongful Conviction Review Unit Amid Federal Funding Dispute

Minnesota Attorney General Keith Ellison has officially suspended operations at the state’s Conviction Review Unit, citing the termination of essential federal grant funding by the Trump administration. The unit, established in 2020 to re-examine cases of potential wrongful convictions, operated on a patchwork of federal grants totaling $800,000 ov…

Contineum Therapeutics CEO Executes Stock Transactions Under 10b5-1 Plan

Contineum Therapeutics CEO Executes Stock Transactions Under 10b5-1 Plan

Carmine N. Stengone, Chief Executive Officer and President of Contineum Therapeutics, Inc. (NASDAQ: CTNM), has executed a series of stock transactions involving both sales and acquisitions. These activities, conducted under a pre-arranged 10b5-1 trading plan, include the sale of 10,000 shares at a weighted average price of $16.008 and the acquisiti…

CoreWeave Executive Offloads $18.3M in Stock Ahead of Valuation Shift

CoreWeave Executive Offloads $18.3M in Stock Ahead of Valuation Shift

CoreWeave, Inc. (CRWV) Chief Development Officer Brannin McBee sold 194,000 shares of Class A Common Stock on June 29, 2026, realizing approximately $18.3 million. The transaction, facilitated by a Rule 10b5-1 trading plan established in March 2026, occurred at prices between $90.24 and $98.31 per share. This activity follows a recent 15% decline i…